Sanctuary Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Sanctuary Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$228K	Buy	+854	New	+$199K	﹤0.01%	2530
2025 Q1	–	Sell	-1,597	Closed	-$203K	–	2201
2024 Q4	$203K	Buy	+1,597	New	+$210K	﹤0.01%	2242

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sanctuary Advisors's ASND Position: Q2 2026 in Review

Sanctuary Advisors opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 854 shares worth $228K. The stake represents ﹤0.01% of the portfolio and ranks #2530 among its holdings. This is a return to the name: Sanctuary Advisors previously reported a position in ASND as recently as Q4 2024.

Sanctuary Advisors first reported a position in ASND in Q4 2024 and has held it in 2 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Sanctuary Advisors held 854 shares of Ascendis Pharma A/S worth $228K as of Q2 2026.
Ascendis Pharma A/S was a new Sanctuary Advisors position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2530 holding.
Sanctuary Advisors first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 2 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.